Central Research Laboratories

Central Research Laboratories Introduces New E Rapid Transfer Port Model

Retrieved on: 
Wednesday, November 9, 2022
Transfer, New, Software, Informal value transfer system, RTP, Redwing, CRL, DOV, Solution, NYSE, Maintenance, Sustainable Technology Optimization Research Center, Körber Process Solutions, Central Research Laboratories, Project, Plastech Engineered Products, Family, Climate, RTPS, Online shopping

DOWNERS GROVE, Ill., Nov. 9, 2022 /PRNewswire/ -- Central Research Laboratories(CRL) , part of Destaco and Dover (NYSE: DOV), and a global leader in the remote-handling industry, today announced the release of the E Rapid Transfer Port (ERTP), a new model in its Rapid Transfer Port product family.

Key Points: 
  • DOWNERS GROVE, Ill., Nov. 9, 2022 /PRNewswire/ -- Central Research Laboratories(CRL) , part of Destaco and Dover (NYSE: DOV), and a global leader in the remote-handling industry, today announced the release of the E Rapid Transfer Port (ERTP), a new model in its Rapid Transfer Port product family.
  • For 25 years, CRL has been designing its RTPs for use as transfer solutions in Life Science applications where cleanability and cleanliness are critical.
  • Headquartered in Red Wing, MN, USA, Central Research Laboratories (CRL) became a Destaco company in 2007.
  • It possesses more than 70 years of innovation experience in the development of remote-handling systems, including Telemanipulators, Transfer Systems, Glove Ports and Waste Drum Transfer Systems.

ObsEva Announces UK MHRA Marketing Authorization for Yselty® (linzagolix), an Oral GnRH Antagonist, for the Treatment of Uterine Fibroids

Retrieved on: 
Tuesday, June 28, 2022
SIX Swiss Exchange, Patient, Gynaecology, Marketing, Company, Hormone, Birth, MHRA, Royal commission, Birth certificate, Quality of life, Urology, Osteoporosis, Drug development, Nasdaq, Pregnancy, Coronavirus, Uterine fibroid, NDA, Security (finance), FDA, European, ABT, Woman, Anemia, Nephrology Dialysis Transplantation, Uterus, SEC, Risk, Central Research Laboratories, Solution, CEO, Report, New Drug Application, Linzagolix, European Commission, Menopause, Investor, Private Securities Litigation Reform Act, Health, U.S. Securities and Exchange Commission, NASDAQ, Mental health, Bloating, Review, Anxiety, Fertility, Adult, Pain, Theramex, Endometriosis, Gonadotropin-releasing hormone, PDUFA, Medicines and Healthcare products Regulatory Agency, Medical device, Pharmaceutical industry, Birth control, EU, Kissei, UF

Yselty is the only approved oral GnRH antagonist to offer flexible dosing options, with and without additional hormonal therapy, for women suffering from UF.

Key Points: 
  • Yselty is the only approved oral GnRH antagonist to offer flexible dosing options, with and without additional hormonal therapy, for women suffering from UF.
  • The MHRA approval follows the granting of marketing authorization by the European Commission earlier in June 2022.
  • For women with UF who cannot or do not want to take hormones, Yselty is the first and only approved oral GnRH antagonist with a non-hormonal dosing option.
  • As the first and only approved GnRH antagonist to offer flexible dosing options with and without additional hormonal therapy, we hope to redefine care for women suffering from uterine fibroids.

Theramex Announces European Commission Marketing Authorization for Yselty® (linzagolix), an Oral GnRH Antagonist, for the Treatment of Symptoms of Uterine Fibroids

Retrieved on: 
Friday, June 17, 2022
Medical Supplies, Health, Consumer, Women, Pharmaceutical, Biotechnology, Solution, Gonadotropin-releasing hormone, Fertility, Uterine fibroid, Nasdaq, CHMP, Menopause, Contraindication, Endometriosis, Urology, Theramex, Central Research Laboratories, Pregnancy, Linzagolix, SIX Swiss Exchange, Kissei, Birth, Committee, Physician, Health, Nephrology Dialysis Transplantation, European Commission, European Directive on Traditional Herbal Medicinal Products, Partnership, Adult, Patient, Life, Committee for Medicinal Products for Human Use, Osteoporosis, ABT, Woman, EC, Pharmaceutical industry, UF, EU

The European Commission (EC) has granted Marketing Authorization for Yselty (linzagolix), an oral GnRH antagonist, indicated for the treatment of moderate to severe symptoms of Uterine Fibroids (UF) in adult women (over 18 years of age) of reproductive age.

Key Points: 
  • The European Commission (EC) has granted Marketing Authorization for Yselty (linzagolix), an oral GnRH antagonist, indicated for the treatment of moderate to severe symptoms of Uterine Fibroids (UF) in adult women (over 18 years of age) of reproductive age.
  • The EC decision follows the Committee for Medicinal Products for Human Use (CHMP) confirmation of positive opinion in April 2022.
  • Linzagolix is the only approved oral GnRH antagonist to offer flexible dosing options, with and without additional hormonal therapy, for women suffering from UF.
  • Uterine Fibroids affect 25% of women within reproductive age, many with severe symptoms requiring surgery.

CALPORTLAND® WELCOMES HAMED MARAGHECHI AS DIRECTOR OF THE CENTRAL RESEARCH LABORATORY

Retrieved on: 
Friday, June 10, 2022
Central Research Laboratories, Pennsylvania State University, Goal, Research, Boral, Greenhouse, Safety, Doctor of Philosophy, University, Biophysical environment, Senior, Multimedia, EPFL, Publication, University of Hawaiʻi, Industry, Master, Civil engineering, CO2, View, Carbon, Science, Fortera Stadium

GLENDORA, Calif., June 10, 2022 /PRNewswire/ -- CalPortland is pleased to announce that Hamed Maraghechi has joined the company as Director of the Central Research Laboratory.

Key Points: 
  • GLENDORA, Calif., June 10, 2022 /PRNewswire/ -- CalPortland is pleased to announce that Hamed Maraghechi has joined the company as Director of the Central Research Laboratory.
  • "Hamed brings valuable experience to CalPortland which will provide strategic guidance for the research and development of new, lower carbon cementitious materials that is instrumental to CalPortland reaching our carbon neutrality goals," said Steve Regis, Senior Vice President, Cement Operations.
  • Hamed joins CalPortland with extensive research experience with cementitious and concrete materials.
  • Hamed has authored and contributed to numerous research publications and presentations involving cement and concrete materials.

New Single-Use Beta Bags from Central Research Laboratories Improve Cost and Efficiency in the Manufacturing of Critical Life Science Products

Retrieved on: 
Wednesday, May 18, 2022
Transfer, HDPE, Software, Redwing, Gamma, VP, Körber Process Solutions, Family, Informal value transfer system, GM, New, Bacteria, Solution, List of life sciences, Central Research Laboratories, CRL, Needle, Sustainable Technology Optimization Research Center, Plastech Engineered Products, DOV, Climate, NYSE, Fine chemical

Single-Use Beta Bags are indispensable components in ready-to-use, component-transfer and waste-handling applications during the manufacturing of Life Science products.

Key Points: 
  • Single-Use Beta Bags are indispensable components in ready-to-use, component-transfer and waste-handling applications during the manufacturing of Life Science products.
  • The new 190-mm Single-Use Beta Bags are available in two materials, Tyvek and HDPE (Tyvek-free), and designed for use with DTPE-style alpha ports.
  • CRL has a ready inventory of the new Single-Use Beta Bags on hand, which allows them to be shipped anywhere in the world.
  • Headquartered in Red Wing, MN, USA, Central Research Laboratories (CRL) became a Destaco company in 2007.

ObsEva Announces Confirmation of Positive CHMP Opinion for Linzagolix, an Oral GnRH Antagonist, for the Treatment of Uterine Fibroids

Retrieved on: 
Monday, April 25, 2022
EMA, Hormone, Nasdaq, Pain, Uterine fibroid, Osteoporosis, Woman, Menopause, Security (finance), NASDAQ, Risk, Patient, PDUFA, Review, Royal commission, UF, U.S. Securities and Exchange Commission, European Commission, Central Research Laboratories, Urology, FDA, Health, Investor, Drug development, Food, Private Securities Litigation Reform Act, Syneos Health, CCO, Theramex, Linzagolix, Endometriosis, Pregnancy, Company, Solution, Contract research organization, Food and Drug Administration, Committee, CEO, European Medicines Agency, Birth certificate, SIX Swiss Exchange, CRO, SEC, Coronavirus, New Drug Application, CHMP, Gonadotropin-releasing hormone, Gynaecology, Clinical trial, EC, Birth, Fertility, Pharmaceutical industry, Kissei

The positive CHMP opinion, which was initially adopted on December 16, 2021, was confirmed at the April 2022 CHMP meeting following further review of the linzagolix marketing authorization application.

Key Points: 
  • The positive CHMP opinion, which was initially adopted on December 16, 2021, was confirmed at the April 2022 CHMP meeting following further review of the linzagolix marketing authorization application.
  • European Commission decisions are valid in the European Union Member States, as well as Iceland, Norway, and Liechtenstein.
  • ObsEva has entered into a licensing agreement with Theramex to support the commercialization and market introduction of linzagolix in Europe.
  • Linzagolix has completed clinical trial development for the treatment of uterine fibroids and is currently in late-stage clinical development for the treatment of pain associated with endometriosis.